MedTrace Logo

A Study to Investigate the Effect of a Nitric Oxide Supplementation on Pre- and Mildly Hypertensive Adults

NCT02679248 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2018-04-12

No results posted yet for this study

Summary

This study will investigate the effect of a nitric oxide supplementation product, Neo40 Daily®, on blood pressure in pre-hypertensive and mildly hypertensive adults. Subjects will take 2 lozenges per day 12 hours apart for 8 weeks. Half of the subjects will receive Neo40 Daily® and the other half of the subjects will receive placebo.

Conditions

  • Pre-hypertension

Interventions

DIETARY_SUPPLEMENT

Neo40 Daily®

DIETARY_SUPPLEMENT

Placebo

Sponsors & Collaborators

  • Neogenis Laboratories

    collaborator OTHER

  • KGK Science Inc.

    lead INDUSTRY

Principal Investigators

  • Tetyana Pelipyagina, MD · KGK Science Inc.

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-02-03
Primary Completion
2017-02-03
Completion
2017-03-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02679248 on ClinicalTrials.gov